At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 45 enrolled
Drug / intervention
Androgen Deprivation Therapy (ADT) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Stereotactic Body Radiation Therapy and Short-Term Androgen Ablation for Intermediate-Risk, Localized, Adenocarcinoma of the Prostate
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·interventional·Posted Jan 25, 2012·Updated Feb 11, 2026
In Brief
A Phase 2 clinical trial evaluating Radiation Therapy and Androgen Deprivation Therapy (ADT) for Adenocarcinoma of the Prostate. Completed, enrolled 45 participants across 3 sites.
Detailed Summary
A study to see how effective and tolerable radiation therapy along with androgen deprivation therapy is in treating prostate cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdenocarcinoma of the Prostate
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJan 2012
Enrollment StartMay 2013
Primary CompletionFeb 2024
Study CompletionDec 2025
TodayJul 2026
First PostedJan 25, 2012
Enrollment StartMay 22, 2013
Primary CompletionFeb 28, 2024
Study CompletionDec 31, 2025
TodayJul 2, 2026
Enrollment to primary: 10.8 yearsPosted 14.4 years ago
Interventions
Radiation Therapyradiation
7.25 Gy every other day fractions to a total dose of 36.25 Gy (total of 5 fractions)
Androgen Deprivation Therapy (ADT)drug
Androgen deprivation therapy (ADT) for 4 months total, greater than or equal to 1 month prior to SBRT.